



H.C. Wainwright Initiates Coverage on SINTX Technologies with Buy Rating, Highlighting Silicon Nitride Platform Opportunity

April 13, 2026

H.C. Wainwright Initiates Coverage on SINTX Technologies with Buy Rating, Highlighting Silicon Nitride Platform Opportunity

Independent analyst coverage underscores SINTX's transition to a commercial-stage biomaterials company, citing its silicon nitride technology, recent FDA clearance and first human implant, and a scalable platform strategy across orthopedics and adjacent healthcare markets.



Analyst Coverage

▲SINT SINT

April 2026

Buy



\$10 Price Target ↑